Nathalie Riebel

I am an independent, hands-on, clinical research executive with over 30 years experience in the life science industry.

> 30 years experience

Based on the east coast of the United States, I have worked globally successfully running and completing all types of clinical trials from phase 1 dose escalation to phase 2 adaptive design and global phase 3 trials. Including investigator initiated and master protocols.

13+

years

Working for pharmaceuticals companies in clinical operations and as head of inspection readiness for the oncology franchise

15+

years

For Large and Mid-size CROs in project management,  Portfolio and Program and Team Director

7+

years

Executive and Sr. Vice President in Mid-size to small biotechnology companies, building department, standards, systems and teams

My objective is to be an extension to your leadership team and support your organization, bringing you knowledge needed to achieve your corporate objectives and project milestones.

Get you the answers needed to develop or terminate your asset.

AREAs of Expertise

Product knowledge

    • Monoclonal Antibodies

    • Immuno-modulator

    • Interferons

    • Interleukins

    • Immune Checkpoints

    • Oncolytics

  • T cell activating platforms

    • Tyrosine kinase

    • RAF

    • VEGF

  • Experience in:

    • Breast cancer

    • Ocular Melanoma

    • Cholangiocarcinoma

    • Colorectal

    • Small Cell Lung Cancer

    • Melanoma

    • Head and Neck Cancer

    • Pancreatic and Renal Cancer

    • Acute Myeloid Leukemia

    • Chronic Lymphocytic Leukemia

  • Infantile Hemangioma

Publications

 

  • ASCO 2023 Price KAR, Kaczmar JM, Worden FP, Wood LV, Schaaf DT, Riebel N, Chaney MF, Weiss J. Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 6012-6012. DOI: 10.1200/JCO.2023.41.16_suppl.6012 Published online May 31, 2023.

  • ASCO 2022 Weiss J, Chintakutlawar AV, Price KAR, Kaczmar JM, Riebel N, Bedu-Addo FK, Chaney MF, Wood LV. PDS0101, a novel type I interferon and CD8 T-cell activating immunotherapy, in combination with pembrolizumab I subjects with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma. Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 6041-6041. DOI: 10.1200/JCO.2022.40.16_suppl.6041

  • ESMO TAT 2023 Wood L, McCarthy S, Schaaf D, Riebel N, Jones S, Cotty A, Bick J. HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy. ESMO TAT 2023, Paris, France, March 6-8, 2023. Abstract 246.

  • ESMO 2023 Harrington K, Weiss J, Price K, Kaczmar J, Schaaf D, Riebel N, Jones S, Cotty A, McCarthy S, Wood L. Polyfunctional HPV16-specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC).  ESMO 2023, Madrid, Spain, October 20-24, 2023. Final Publication Number [FPN] 924P. (Note: the submitted assigned abstract # was 6982).